glp-1 drug news The promises and pitfalls of drugs GLP-1 Agonists Weight Loss Drugs
Description
The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157
The GLP-1 receptor agonist market is experiencing significant growth, driven by the increasing prevalence of type 2 diabetes and obesity, and the high...
Novo Nordisk announced that its rebranded and reformulated oral GLP-1 medication, formerly known as Rybelsus, is now available in the U.S
It has been studied in human clinical trials and shown to support metabolic balance, healthy blood glucose regulation, inflammation management, and improved insulin function
Individual results may vary
Albert, MBA, PharmD, JD, DASPL
